And prices are getting slimmer: PROMOMED has reduced the cost of the drug Tirzetta® 2.5 mg

Medicines

Industry development

13.02.2026

PROMOMED, a leading innovative biopharmaceutical company, provides patients with a special opportunity to purchase the drug Tirzetta® (INN tirzepatide) in a dosage of 2.5 mg with a benefit of up to 2,000 rubles. Special conditions apply to the starting dosage used at the beginning of therapy to make the first stage of treatment more comfortable for patients. The drug is available in pharmacy chains and online pharmacy resources throughout the country. The company's solution is aimed at increasing the availability of modern therapy.

The opportunity to purchase Tirzetta® at a dosage of 2.5 mg under special conditions has become a reality due to the scaling of production, optimization of operational processes and the implementation of the full cycle concept. Tirzetta® is the first domestic tirzepatide fully manufactured in Russia at PROMOMED's facilities, from the substance to the finished dosage form. By expanding its affordability, the company aims to provide more patients with innovative treatment.
The range of dosages remains, each package of four disposable auto-injectors is designed for a monthly course of use. The drug complies with current quality and safety requirements.[1]

"PROMOMED, an expert in the field of endocrinology and the treatment of overweight and obesity, consistently implements a strategy to expand access to modern therapy. Reducing the retail price of Tirzetta® at a dosage of 2.5 mg is an important step that makes the start of therapy more accessible to patients. We continue to invest in the development of production facilities and the introduction of advanced technologies, ensuring the sustainable presence of domestic innovative drugs on the market."